as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹21,440.0
Change
-450.0 (-2.06%)
Open
₹21,890.0
Prev. Close
₹21,890.0
Day High
₹21,920.0
Day Low
₹21,395.0
Volume Analysis
Traded
18,960
Delivered
8,196
Delivery %
43.23%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (21.2%)
- •Strong operating margin (32.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (30.6%)
- •Strong 3-year revenue growth (19.3%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹22,300.0 | ₹22,110.0 | ₹21,775.0 | ₹21,585.0 | ₹21,250.0 | ₹21,060.0 | ₹20,725.0 |
| Fibonacci | ₹22,110.0 | ₹21,909.45 | ₹21,785.55 | ₹21,585.0 | ₹21,384.45 | ₹21,260.55 | ₹21,060.0 |
| Camarilla | ₹21,584.38 | ₹21,536.25 | ₹21,488.13 | ₹21,585.0 | ₹21,391.88 | ₹21,343.75 | ₹21,295.63 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+42.36%
1 Week
-4.92%
1 Month
-7.61%
3 Months
+14.13%
6 Months
+72.44%
1 Year
+48.55%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹3,053.89
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
22.59%
Net margin 20.99% × asset turnover 0.69x × equity multiplier 1.56x
Company Overview
Sector
Healthcare
Market Cap
₹28,085 Cr
P/E (TTM)
56.4
ROE
21.2%
Book Value
₹1,461.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Neuland Lab Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (21.2%); strong operating margin (32.0%); promoter holding is falling. Strong 3-year EPS growth (30.6%).
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 38.5% CAGR over last 5 years
- −Stock is trading at 15.0 times its book value
- −Promoter holding has decreased over last 3 years: -3.41%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 - 25, 2026
First commercial peptide module operational; second module expansion underway after $30 million investment.
Intimation about Schedule of Analyst / Institutional Investor Meeting on September 15, 2026 and September 17, 2026
Board approved ₹126 crore purchase of 134 acres at Kakinada, with ROFR for 66 more acres.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses + | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 |
| Operating Profit | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 |
| OPM % | 27.0% | 33.0% | 31.0% | 28.0% | 28.0% | 20.0% | 22.0% | 16.0% | 12.0% | 30.0% | 18.0% | 40.0% | 35.0% |
| Other Income + | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 |
| Tax % | 26.0% | 27.0% | 22.0% | 27.0% | 25.0% | 34.0% | 20.0% | 29.0% | 21.0% | 25.0% | 26.0% | 26.0% | 25.0% |
| Net Profit + | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| EPS in Rs | 48 | 70 | 63 | 53 | 76 | 26 | 79 | 22 | 11 | 75 | 32 | 166 | 115 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,372 |
| Expenses + | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,443 | 1,609 |
| Operating Profit | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 580 | 763 |
| OPM % | 14.0% | 16.0% | 18.0% | 10.0% | 9.0% | 13.0% | 16.0% | 15.0% | 23.0% | 30.0% | 22.0% | 29.0% | 32.0% |
| Other Income + | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 25 | 31 |
| Interest | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 24 | 26 |
| Depreciation | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 92 | 98 |
| Profit before tax | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 489 | 669 |
| Tax % | 36.0% | 36.0% | 30.0% | 13.0% | 19.0% | 69.0% | 23.0% | 22.0% | 24.0% | 25.0% | 25.0% | 26.0% | — |
| Net Profit + | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 | 498 |
| EPS in Rs | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 50 | 127 | 234 | 203 | 284 | 388 |
| Dividend Payout % | 8.0% | 7.0% | 0.0% | 0.0% | 0.0% | 16.0% | 8.0% | 10.0% | 8.0% | 6.0% | 6.0% | 12.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 | 1,862 |
| Borrowings + | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | 301 |
| Other Liabilities + | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 | 754 |
| Total Liabilities | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 |
| Fixed Assets + | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 | 1,177 |
| CWIP | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 | 211 |
| Investments | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 2 |
| Other Assets + | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 | 1,541 |
| Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,930 |
| Equity Capital | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | 261 | 317 | 347 |
| Cash from Investing Activity + | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -95 | -61 | -150 | -298 | -423 |
| Cash from Financing Activity + | 1 | -24 | 0 | 105 | 12 | -5 | -114 | 38 | -136 | -69 | 25 | 21 |
| Net Cash Flow | 0 | 1 | -4 | 0 | 5 | 3 | -9 | 3 | 40 | 42 | 44 | -55 |
| CFO/OP | 33 | 70 | 52 | 28 | 128 | 61 | 132 | 56 | 103 | 81 | 119 | 78 |
| Free Cash Flow | -1 | 26 | -2 | -121 | 7 | 9 | 84 | -37 | 173 | 119 | 112 | -50 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 35.08% | 38.1% | 35.88% | 34.77% | 34.12% | 33.96% | 33.85% | 33.67% | 32.8% | 31.76% | 31.08% | 29.79% |
| Promoters | 35.97% | 32.8% | 32.74% | 32.72% | 32.64% | 32.68% | 32.67% | 32.67% | 32.64% | 32.63% | 32.63% | 32.62% |
| Government | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% |
| FII | 21.57% | 22.69% | 24.43% | 25.72% | 26.46% | 23.86% | 22.12% | 21.69% | 20.6% | 20.9% | 20.46% | 21.08% |
| DII | 6.99% | 6.02% | 6.54% | 6.39% | 6.38% | 9.09% | 10.97% | 11.57% | 13.55% | 14.72% | 15.84% | 16.52% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Neuland Lab Ltd. (this stock) | 28,085 | 56.4 | 14.98 | 21.2% |
| Piramal Pharma Limited | 28,000 | — | 3.42 | -3.83% |
| Rubicon Research Limited | 27,748 | 96.3 | 21.46 | 27.0% |
| Acutaas Chemicals Limited | 26,884 | 69.6 | 16.26 | 24.0% |
| Dr. Lal Path Labs Ltd. | 32,299 | 57.4 | 12.83 | 22.3% |
| Krishna Inst Of Med Sci L | 32,765 | 157.0 | 13.88 | 11.3% |
| Granules India Limited | 23,248 | 35.8 | 4.16 | 13.8% |
Which Mutual Funds Hold Neuland Lab Ltd.?
Frequently Asked Questions about Neuland Lab Ltd.
Neuland Lab Ltd. (NEULANDLAB) closed at ₹21,440.0 on NSE on 28 September 2026, down 450.0 (2.06%) from the previous close.
Neuland Lab Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NEULANDLAB.
Neuland Lab Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 56.4.
Neuland Lab Ltd. has a dividend yield of 0.16%.
Neuland Lab Ltd.'s 52-week high is ₹24,235.0 and its 52-week low is ₹11,500.0.
Neuland Lab Ltd. has a market capitalisation of ₹28,085 crore.
Neuland Lab Ltd. has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Neuland Lab Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.